Monte Rosa Therapeutics, Inc. (GLUE)
After hours:
| Previous close | 3.3800 |
| Open | 3.3200 |
| Bid | 3.6200 x 100 |
| Ask | 3.7400 x 2200 |
| Day's range | 3.2100 - 3.7400 |
| 52-week range | 2.4400 - 8.8400 |
| Volume | |
| Avg. volume | 207,450 |
| Market cap | 228.703M |
| Beta (5Y monthly) | 1.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.00 |
GlobeNewswireMonte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024 IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinica
- GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 2025 Poster presentation today at 14:45 CET / 8:45 a.m. ET BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel mole
Simply Wall St.Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)
Key Insights Institutions' substantial holdings in Monte Rosa Therapeutics implies that they have significant influence...
